Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Achievement of Sustained Molecular Remission Induces Long-Term Freedom From Disease After Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma

Nicolaus Kröger, Tatjana Zabelina, MD, Francis Ayuk, MD, Christine Wolschke, MD, Haefaa Alchalby, Anita Badbaran, Djordje Atanackovic, M.D., Georgia Schilling, MD, Orhan Sezer, MD, PhD, Ulrike Bacher, MD, Thomas Stübig, MD, Boris Fehse, Ph.D., Axel R. Zander, MD

Blood (2011) 118 (21): 148.

https://doi.org/10.1182/blood.V118.21.148.148

Published: 2011

Journal Articles

Lenalidomide Maintenance Therapy After Toxicity-Reduced Myeloablative Allograft As Salvage Therapy for Efractory/Relapsed Myeloma Patients

Nicolaus Kröger, Evgeny Klyuchnikov, MD, Thomas Stübig, MD, Christine Wolschke, MD, Francis Ayuk, MD, Tatjana Zabelina, MD, York Hildebrandt, Ulrike Bacher, MD, Anita Badbaran, Georgia Schilling, MD, Orhan Sezer, MD, PhD, Djordje Atanackovic, M.D., Martin Kropff, MD, Axel R. Zander, MD

Blood (2011) 118 (21): 3024.

https://doi.org/10.1182/blood.V118.21.3024.3024

Published: 2011

Journal Articles

Incidence of ETV6 Cryptic Translocations In Myeloid Disorders

Eva Maria Murga Penas, PhD, Marianne Klokow, Petra Behrmann, Snjezana Janjetovic, MD, Georgia Schilling, MD, Carsten Bokemeyer, MD, Judith Dierlamm, MD, PhD

Blood (2010) 116 (21): 2733.

https://doi.org/10.1182/blood.V116.21.2733.2733

Published: 2010

Journal Articles

Chromosomes 2q, 4q and 13q21 Are Preferential Targets of Epstein-Barr Virus (EBV) Integration In Burkitt's Lymphoma Cell Lines

Eva Maria Murga Penas, PhD, Juliane Hinke, Petra Behrmann, Snjezana Janjetovic, MD, Georgia Schilling, MD, Carsten Bokemeyer, MD, Judith Dierlamm, MD, PhD

Blood (2010) 116 (21): 4452.

https://doi.org/10.1182/blood.V116.21.4452.4452

Published: 2010

Journal Articles

Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial

Blood (2008) 112 (11): 2776.

https://doi.org/10.1182/blood.V112.11.2776.2776

Published: 2008

Journal Articles

No Adverse Impact of 13q14 and P53 Deletion, t(4;14)(p16;q32) or Overrepresentation of CMYC(8q24) as Detected by Fluorescence In Situ Hybridization on Outcome in Patients with Multiple Myeloma Following Dose-Reduced Allogeneic Stem Cell Transplantation.

Timon Hansen, Georgia Schilling, MD, Peter Liebisch, MD, Rainer Schwerdtfeger, PD, Jose Antonio Perez-Simon, MD, Martin Bornhaeuser, PD, Svenja Otterstetter, Judith Dierlamm, PD, Arnon Nagler, Dieter Kurt Hossfeld, Carsten Bokemeyer, Axel R. Zander, Nicolaus Kroeger, PD

Blood (2006) 108 (11): 5038.

https://doi.org/10.1182/blood.V108.11.5038.5038

Published: 2006

Journal Articles

Deletion of p53 as Detected by Fluorescence In Situ Hybridization Is Associated with Significant Shorter Event-Free Survival in Patients with Multiple Myeloma Who Are Receiving Allogeneic Blood Stem Cell Transplantation.

Georgia Schilling, MD, Timon Hansen, Jose Antonio Perez-Simon, MD, Rainer Schwerdtfeger, MD, Martin Bornhaeuser, MD, Svenja Otterstetter, Doris Seeger, Judith Dierlamm, PD, Francis Ayuk, MD, Hossfeld Dieter Kurt, Bokemeyer Carsten, Zander R. Axel, Kroeger Nicolaus, PD

Blood (2005) 106 (11): 4338.

https://doi.org/10.1182/blood.V106.11.4338.4338

Published: 2005

NARROW

Achievement of Sustained Molecular Remission Induces Long-Term Freedom From Disease After Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma

Lenalidomide Maintenance Therapy After Toxicity-Reduced Myeloablative Allograft As Salvage Therapy for Efractory/Relapsed Myeloma Patients

Incidence of ETV6 Cryptic Translocations In Myeloid Disorders

Chromosomes 2q, 4q and 13q21 Are Preferential Targets of Epstein-Barr Virus (EBV) Integration In Burkitt's Lymphoma Cell Lines

Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial

No Adverse Impact of 13q14 and P53 Deletion, t(4;14)(p16;q32) or Overrepresentation of CMYC(8q24) as Detected by Fluorescence In Situ Hybridization on Outcome in Patients with Multiple Myeloma Following Dose-Reduced Allogeneic Stem Cell Transplantation.

Deletion of p53 as Detected by Fluorescence In Situ Hybridization Is Associated with Significant Shorter Event-Free Survival in Patients with Multiple Myeloma Who Are Receiving Allogeneic Blood Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Achievement of Sustained Molecular Remission Induces Long-Term Freedom From Disease After Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma

Lenalidomide Maintenance Therapy After Toxicity-Reduced Myeloablative Allograft As Salvage Therapy for Efractory/Relapsed Myeloma Patients

Incidence of ETV6 Cryptic Translocations In Myeloid Disorders

Chromosomes 2q, 4q and 13q21 Are Preferential Targets of Epstein-Barr Virus (EBV) Integration In Burkitt's Lymphoma Cell Lines

Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial

No Adverse Impact of 13q14 and P53 Deletion, t(4;14)(p16;q32) or Overrepresentation of CMYC(8q24) as Detected by Fluorescence In Situ Hybridization on Outcome in Patients with Multiple Myeloma Following Dose-Reduced Allogeneic Stem Cell Transplantation.

Deletion of p53 as Detected by Fluorescence In Situ Hybridization Is Associated with Significant Shorter Event-Free Survival in Patients with Multiple Myeloma Who Are Receiving Allogeneic Blood Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only